A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2018
At a glance
- Drugs Vonlerolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 30 May 2017 Planned End Date changed from 31 Dec 2017 to 23 Jun 2018.
- 30 May 2017 Planned primary completion date changed from 31 Dec 2017 to 23 Jun 2018.
- 30 May 2017 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History